Shailly Mehrotra

发表

Pediatric Formulation Development - Challenges of Today and Strategies for Tomorrow: Summary Report from M-CERSI Workshop 2019.

S. Hoag, J. Walsh, E. Galella, 2021, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies

J. Gobburu, J. Karp, M. Rudek, 2017, Clinical Cancer Research.

Exposure–ResponseofVeliparib to InformPhase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies

J. Gobburu, J. Karp, M. Rudek, 2017 .

Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies

J. Gobburu, J. Karp, M. Rudek, 2017, British journal of clinical pharmacology.

Pharmacometrics‐guided drug development of antihyperhidrosis agents

J. Gobburu, T. P. Dumitrescu, Shailly Mehrotra, 2015, Journal of clinical pharmacology.

Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration

J. Gonzales, D. Nicolau, Shailly Mehrotra, 2015, Antimicrobial Agents and Chemotherapy.

Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias

A. Chen, J. Gobburu, J. Karp, 2018, Cancer Chemotherapy and Pharmacology.

Parent‐Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients With BRCA 1/2–Mutated Cancer or PARP‐Sensitive Tumor Types

V. Ivaturi, J. Gobburu, E. Chu, 2017, Journal of clinical pharmacology.

A Randomized Trial of Vedolizumab Dose Optimization in Patients With Moderate to Severe Ulcerative Colitis Who Have Early Nonresponse and High Drug Clearance: The ENTERPRET Trial.

V. Jairath, Shailly Mehrotra, M. Osterman, 2022, Gastroenterology & hepatology.

Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)

E. Winer, M. Ratain, C. Hudis, 2019, Journal of clinical pharmacology.

Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder

N. Desousa, J. Gobburu, B. Incledon, 2017, Journal of child and adolescent psychopharmacology.

Extrapolation of Efficacy from Adults to Pediatric Patients of Drugs for Treatment of Partial Onset Seizures: A Regulatory Perspective

B. Dunn, R. Uppoor, E. Bastings, 2022, Clinical pharmacology and therapeutics.

Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)

E. Winer, M. Ratain, C. Hudis, 2017, The AAPS Journal.

Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults

Yiyun Huang, R. Carson, N. Nabulsi, 2022, Journal of Psychopharmacology.

Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)

E. Winer, M. Ratain, C. Hudis, 2017, The AAPS Journal.

Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration

J. Gonzales, D. Nicolau, Shailly Mehrotra, 2015, Antimicrobial Agents and Chemotherapy.